Artemisinin-resistant malaria in Ethiopia
Epidemiology and determinants of emerging artemisinin-resistant malaria in Ethiopia
['FUNDING_R01'] · UNIV OF NORTH CAROLINA CHAPEL HILL · NIH-11094701
Researchers are looking at why some malaria infections in people in Ethiopia don't respond to artemisinin-based medicines and sometimes avoid common rapid tests.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIV OF NORTH CAROLINA CHAPEL HILL (nih funded) |
| Locations | 1 site (CHAPEL HILL, UNITED STATES) |
| Trial ID | NIH-11094701 on ClinicalTrials.gov |
What this research studies
If I join, clinic staff in Ethiopia would collect a small sample when I come in with malaria symptoms and test the parasites' genes to see if they carry drug-resistance or diagnostic-evasion changes (like K13 R622I or HRP2/3 deletions). The team will also ask about where I live, recent travel, treatment history, and other factors that might make someone more likely to have these resistant infections. Researchers will compare samples and survey answers across multiple health sites in Ethiopia to find patterns that explain who gets these resistant parasites. The findings are meant to help doctors and public health officials improve which medicines and rapid tests are used where.
Who could benefit from this research
Good fit: Ideal participants are people in Ethiopia who come to participating health clinics with confirmed or suspected Plasmodium falciparum malaria.
Not a fit: People without falciparum malaria, those infected with other malaria species, or anyone living outside the study areas in Ethiopia are unlikely to directly benefit.
Why it matters
Potential benefit: If successful, the work could help clinicians pick effective medicines and improve malaria tests so patients get faster, more reliable care.
How similar studies have performed: Other field studies have already identified K13 mutations and HRP2 deletions in Africa, so this work builds on existing genomic surveillance while adding clinic-based risk-factor analysis.
Where this research is happening
CHAPEL HILL, UNITED STATES
- UNIV OF NORTH CAROLINA CHAPEL HILL — CHAPEL HILL, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PARR, JONATHAN BOYD — UNIV OF NORTH CAROLINA CHAPEL HILL
- Study coordinator: PARR, JONATHAN BOYD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.